Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
26.76%
Operating Margin
11.59%
Net Margin
10.52%
Efficiency Metrics
Revenue per Expense Ratio
1.13
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
18.44%
Income Tax Rate
14.22%
EPS
2.1400000000
Balance Sheet Analysis
Current Ratio
1.47
Cash Ratio
0.61
Working Capital
$4.41B
Debt to Equity
0.64
Debt to Assets
27.29%
Equity Ratio
42.79%
Cash Flow Analysis
Operating Cash Flow Ratio
16.38%
Free Cash Flow Ratio
15.36%
CapEx to Revenue
1.02%
Dividends Paid
$750.37M
Stock Buybacks
$69.29M
Total Shareholder Returns
$819.66M
Cash Position Change
110.37%
Key Takeaways (2023 FY)
Revenue declined by 2.0442297674254%, indicating potential market challenges
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
-2.04%
Net Income
103.13%
EPS
93.16%
Operating Income
152.06%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
52.34%
Operating Cash Flow
-9.84%
Free Cash Flow
12.05%
Balance Sheet Health
Assets
12.30%
Debt
20.29%
Book Value per Share
4.59%
Inventory
-10.33%
Shareholder Returns
Dividends per Share
-68.38%
Shares Outstanding
9.46%
Long Term Trends
3Y Revenue/Share
5.31%
5Y Revenue/Share
31.39%
3Y Dividend/Share
9.45%
5Y Dividend/Share
127.96%